Small ubiquitin-like modifiers inhibitors lower blood pressure via ERK5/KLF2-dependent upregulation of the eNOS/NO pathway

Small ubiquitin-like modifiers inhibitors lower blood pressure via ERK5/KLF2-dependent upregulation of the eNOS/NO pathway

Small ubiquitin-like modifiers (SUMO)ylation is a dynamic and reversible post-translational modification playing pivotal roles in the regulation of cancer, diabetes, heart failure, and neurological diseases. However, whether SUMO inhibitors also have anti-hypertension effect remains yet to be explor...

Full description

Saved in:
Bibliographic Details
Main Authors: Tang Nannan, Li Jiatong, Wang Zhuo, Zuo Jinlu, Zhang Zifeng, Huang Di, Han Yannan, Chen Yuqing, Sun Yilin, Li Xiang, Mu Ruxue, Ma Qingxue, Zhang Jie, Wu Jiaying, Wang He, Zhao Hongxia, Dong Xingli, Wang Zhiguo, Liu Yu, Zhao Dan, Yang Baofeng
Format: Article
Language:English
Published: De Gruyter 2025-01-01
Series:Frigid Zone Medicine
Subjects:
hypertension
sumo inhibitor
erk5
sumoylation
klf2
Online Access:https://doi.org/10.1515/fzm-2024-0020
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small ubiquitin-like modifiers (SUMO)ylation is a dynamic and reversible post-translational modification playing pivotal roles in the regulation of cancer, diabetes, heart failure, and neurological diseases. However, whether SUMO inhibitors also have anti-hypertension effect remains yet to be explored.
ISSN:2719-8073

Similar Items